The BioNTech SE ADR BNTX rallied 3.82% to $120.21 Monday, on what proved to be an all-around mixed trading session for the ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen ...

Tidal Investments LLC lessened its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 39.5% in the third quarter, according ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

The global pediatric vaccine market is set for unprecedented growth, with a valuation of US$ 54,130.1 million in 2023, ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...